Tobacco dependence is the leading cause of preventable death and disability in the United States. While smoking prevalence among U.S. adults is 19.3%, the prevalence of smoking among methadone-maintained patients ranges between 73.5% and 94%. Most methadone-maintained smokers (76%-80%) desire to quit smoking; however only a minority of these smokers receive cessation treatment or referrals for smoking cessation intervention. Smoking cessation treatment in methadone-maintained patients has generally been successful in reducing the daily number of cigarettes smoked. Unfortunately, sustained cessation rates using nicotine replacement therapy and behavioral interventions have generally been low (0%-11%). Poor cessation outcomes may be partially explained by pharmacodynamic interactions between nicotine and methadone leading to increased reinforcement of smoking behavior. Further research is needed to improve smoking cessation rates in methadone-maintained patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1874473711306010009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and Evaluation of a Digital App for Patient Self-Management of Opioid Use Disorder: Usability, Acceptability, and Utility Study.
JMIR Form Res
April 2024
Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center San Antonio, San Antonio, TX, United States.
Background: Self-management of opioid use disorder (OUD) is an important component of treatment. Many patients receiving opioid agonist treatment in methadone maintenance treatment settings benefit from counseling treatments to help them improve their recovery skills but have insufficient access to these treatments between clinic appointments. In addition, many addiction medicine clinicians treating patients with OUD in a general medical clinic setting do not have consistent access to counseling referrals for their patients.
View Article and Find Full Text PDFPredictors of treatment retention and survival among methadone-maintained patients: A possible role for a functional delta opioid receptor gene variant.
Drug Alcohol Depend
September 2023
The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, United States.
Background: Variants in the delta opioid receptor gene, OPRD1, were associated with opioid use disorder and response to treatment. The study goal was to assess whether OPRD1 variants predict survival and retention in methadone maintenance treatment (MMT).
Methods: Retention and survival time since admission (June 1993 - June 2022) until leaving treatment (for retention), or at the end of follow-up (Dec 2022) (for retention and survival) were analyzed in 488 patients.
Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences.
PLoS One
January 2022
Department of Psychiatry and Behavioural Neurosciences, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
Genetic variants in the OPRM1 and CYP2B6 genes, respectively coding for an opioid receptor and methadone metabolizers, have been linked to negative treatment outcomes in patients undergoing methadone maintenance treatment, with little consensus on their effect. This study aims to test the associations between pre-selected SNPs of OPRM1 and CYP2B6 and outcomes of continued opioid use, relapse, and methadone dose. It also aims to observe differences in associations within the sexes.
View Article and Find Full Text PDFEffect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study.
Drug Alcohol Depend
October 2021
Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, 417 Delaware Street SE, Minneapolis, MN, 55455, USA. Electronic address:
Background: Methadone treatment of opioid use disorder in HIV-infected individuals is complicated by drug-drug interactions. Genetic and other cofactors further contribute to interindividual variability in methadone pharmacokinetics. We used population pharmacokinetics to estimate the effect of drug-drug interactions, genetics, and other cofactors on methadone pharmacokinetics in a methadone maintained population in Vietnam.
View Article and Find Full Text PDFMethadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone.
Drug Alcohol Depend
September 2021
University of California, San Francisco, Department of Psychiatry and Behavioral Sciences, 401 Parnassus Ave, San Francisco, CA, 94143, USA; Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, Ward 95, San Francisco, CA, 94110, USA. Electronic address:
Objectives: Acute pain management in patients with opioid use disorder who are maintained on methadone presents unique challenges due to high levels of opioid tolerance in this population. This randomized controlled study assessed the analgesic and abuse liability effects of escalating doses of acute intravenous (IV) hydromorphone versus placebo utilizing a validated experimental pain paradigm, quantitative sensory testing (QST).
Methods: Individuals (N = 8) without chronic pain were maintained on 80-100 mg/day of oral methadone.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!